GlassScriptPhysician profile
Varduhi Hakopian
NPI 1386329712
$1,381.42
in general payments reported to CMS, 2019-2025
21 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.93 · 2024: $987 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $286.45 | 2024 | Ingrezza |
| Lundbeck LLC | $154.69 | 2024 | Rexulti |
| Ardelyx, INC. | $120.73 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.57 | 2024 | Jardiance |
| Amgen INC. | $86.08 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $78.25 | 2023-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.17 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $72.66 | 2024 | Verquvo |
| Glaxosmithkline, LLC. | $58.54 | 2024-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $55.56 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $43.87 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $34.48 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.99 | 2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $28.38 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $24.48 | 2023 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.11 | 2024 | Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $23.99 | 2024 | |
| Organogenesis INC. | $21.40 | 2024 | Apligraf |
| Astrazeneca Pharmaceuticals LP | $20.38 | 2025 | Breztri |
| Ucb, INC. | $16.75 | 2024 | Zilbrysq |
| Ibsa Pharma INC. | $13.89 | 2025 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varduhi Hakopian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.